Summary Keywords Alzheimers disease, clinical trial, cognitive dysfunction, GLP-1 receptor agonist, neuroinflammation, neuroprotection, semaglutide, vascular dementia Citation Alhowail AH, Al Mouslem AK, Almatrafi MA and Aldubayan MA (2026) Semaglutide in cognitive dysfunction: neuroprotective potential, clinical trial limitations, and a prevention-focused framework
Because bones adapt to the weight they carry, losing weight means less stress on the skeleton, and over time, this can lead to small decreases in bone strength
When people lose weight, their bodies often become more sensitive to insulin, which helps regulate blood sugar levels more effectively
American College of Cardiology 2006 Principles to Guide Physician Pay-for-Performance Programs A Report of the American College of Cardiology Work Group on Pay for Performance (A Joint Working Group of the ACC Quality Strategic Direction Committee and the ACC Advocacy Committee)